GleamWall
中文EN

NEOG NEOGEN CORP

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 711377 · Fiscal year ends 05/31

Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.3%
TTM net income YoY94.6%
TTM EPS YoY94.6%
Revenue 3-yr CAGR-1.3%
Net income 3-yr CAGR—

Margins

Gross margin47.4%
Operating margin-0.8%
Net margin-6.3%
FCF margin5.6%
EBITDA margin12.3%

Returns

ROE-2.7%
ROA-1.7%
ROIC (approx.)-0.2%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets36.8%
Debt / equity0.74x
Current ratio3.90x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.52x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue4.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-05-31FY20252025-05-31
Income statement
Revenue$870.40M$894.66M
Cost of revenue$461.90M$473.30M
Gross profit$408.50M$421.40M
R&D expense$18.40M$21.10M
SG&A expense$245.10M$218.20M
Operating income-$21.60M-$1.06B
Interest expense$24.10M$38.10M
Pretax income-$9.00M-$1.13B
Income tax-$1.10M-$41.10M
Net income-$7.90M-$1.09B
EBITDA$94.70M-$941.50M
EPS (basic)-0.04-5.03
EPS (diluted)-0.04-5.03
Weighted avg. shares (diluted)217.50M216.90M
Balance sheet
Cash & equivalents$185.50M$129.00M
Short-term investments—$0
Receivables$146.80M$153.40M
Inventory$144.30M$190.80M
Current assets$604.60M$576.90M
PP&E, net$329.80M$339.10M
Goodwill$1.05B$1.06B
Intangibles$1.32B$1.41B
Total assets$3.35B$3.44B
Current liabilities$158.20M$174.00M
Short-term debt$800.00M$19.30M
Long-term debt$793.70M$874.80M
Total debt$1.59B$894.10M
Total liabilities$1.25B$1.37B
Shareholders' equity$2.09B$2.07B
Net debt$1.41B$765.10M
Shares outstanding217.70M217.00M
Cash flow statement
Operating cash flow$83.20M$58.20M
Capital expenditure$51.30M$104.60M
Free cash flow$31.90M-$46.40M
Investing cash flow$70.50M-$99.20M
Financing cash flow-$99.40M-$1.60M
Depreciation & amortization$116.30M$119.50M
Stock-based compensation$13.40M$17.30M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.